Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program

Administration for Strategic Preparedness and Response. (2023). Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program. U.S. Department of Health and Human Services.
This guide is intended to provide direction as the U.S. Government (USG) prepares to wind down the current distribution of USG-procured COVID-19 therapeutics and transitions the COVID-19 Oral Antiviral (OAV) treatments (nirmatrelvir packaged with ritonavir [Paxlovid] and molnupiravir [Lagevrio]) to the commercial market. This guide aims to help jurisdictions and providers (1) plan for the transition away from USG ordering; (2) understand the impact of this transition on ordering mechanism; (3) understand how to manage inventory of USG distributed OAV products, including continued reporting requirements for remaining USG inventory; and (4) provide summary information about programs to provide access for uninsured and underinsured individuals once COVID-19 OAVs become commercially available. T
Rate: Favorite:
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.